Cargando…

Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study

BACKGROUND: After more than 2 years of the pandemic, effective treatment for COVID-19 is still under research. In recent months, publications hypothesized amantadine's potential beneficial effect on SARS-CoV-2 infection. OBJECTIVE: To compare the groups of Parkinson's Disease (PD) patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Przytuła, Filip, Kasprzak, Jakub, Dulski, Jarosław, Koziorowski, Dariusz, Kwaśniak-Butowska, Magdalena, Sołtan, Witold, Roszmann, Anna, Śmiłowska, Katarzyna, Schinwelski, Michał, Sławek, Jarosław
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724557/ https://www.ncbi.nlm.nih.gov/pubmed/36509028 http://dx.doi.org/10.1016/j.parkreldis.2022.105238

Ejemplares similares

Arterial Blood Pressure Variability and Other Vascular Factors Contribution to the Cognitive Decline in Parkinson’s Disease
por: Pierzchlińska, Anna, et al.
Publicado: (2021)

Regulation of Mitochondrial Dynamics in Parkinson’s Disease—Is 2-Methoxyestradiol a Missing Piece?
por: Bastian, Paulina, et al.
Publicado: (2021)

Metabolomic Footprint of Disrupted Energetics and Amino Acid Metabolism in Neurodegenerative Diseases: Perspectives for Early Diagnosis and Monitoring of Therapy
por: Maszka, Patrycja, et al.
Publicado: (2023)

Genomic instability in the PARK2 locus is associated with Parkinson’s disease
por: Ambroziak, Wojciech, et al.
Publicado: (2015)

Amantadine, COVID-19 and Parkinsonism
por: Wiwanitkit, Viroj
Publicado: (2020)

Does Ultrasound Guidance Improve the Effectiveness of Neurotoxin Injections in Patients with Cervical Dystonia? (A Prospective, Partially-Blinded, Clinical Study)
por: Tyślerowicz, Małgorzata, et al.
Publicado: (2022)

Response to: Amantadine, COVID-19 and Parkinsonism
por: Aranda-Abreu, Gonzalo Emiliano
Publicado: (2020)

Could amantadine interfere with COVID-19 vaccines based on the LNP-mRNA platform?
por: Fedorowski, Jaroslaw J.
Publicado: (2021)

Amantadine-Induced Patulous Eustachian Tubes in Parkinson's Disease
por: Boyd, J. T., et al.
Publicado: (2013)

Genetic architecture of Parkinson’s disease subtypes – Review of the literature
por: Dulski, Jarosław, et al.
Publicado: (2022)

Huntington’s disease from the patient, caregiver and physician’s perspectives: three sides of the same coin?
por: Banaszkiewicz, Krzysztof, et al.
Publicado: (2012)

Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial
por: Sawada, Hideyuki, et al.
Publicado: (2010)

An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease
por: Kong, Min, et al.
Publicado: (2017)

Investigation of the Long-Term Effects of Amantadine Use in Parkinson’s Disease
por: Park, Sangmin, et al.
Publicado: (2023)

A Patient with Corticobasal Syndrome and Progressive Non-Fluent Aphasia (CBS-PNFA), with Variants in ATP7B, SETX, SORL1, and FOXP1 Genes
por: Gaweda-Walerych, Katarzyna, et al.
Publicado: (2022)

The Effect of Frailty Syndrome on the Quality of Life of Individuals with Parkinson’s Disease: A Pilot Observational and Multicenter Study on the Polish Population
por: Pytel, Aleksandra, et al.
Publicado: (2022)

Amantadine‐Induced Craniofacial Myoclonus: Distinctive Iatrogenic Dysarthria in Parkinson's Disease
por: Lin, Iris, et al.
Publicado: (2023)

Changing phenotypic expression in a patient with a mitochondrial encephalopathy due to 13042G>A de novo mutation—a 5 year follow up
por: Schinwelski, M., et al.
Publicado: (2014)

N-Terminal Pro-Brain Natriuretic Peptide and Right Ventricular Diameter Are Related to Aspirin Resistance in Coronary Artery Disease Patients
por: Cygulska, Kamila Marika, et al.
Publicado: (2021)

Parkinson's disease or atypical parkinsonism? The importance of acoustic voice analysis in differential diagnosis of speech disorders
por: Kowalska‐Taczanowska, Renata, et al.
Publicado: (2020)

Automatic assessment of the motor state of the Parkinson's disease patient--a case study
por: Kostek, Bozena, et al.
Publicado: (2012)

Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson’s Disease
por: Muhlack, Siegfried, et al.
Publicado: (2010)

Neuroprotective effect of Spirulina fusiform and amantadine in the 6-OHDA induced Parkinsonism in rats
por: Chattopadhyaya, I, et al.
Publicado: (2015)

Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)
por: Pahwa, Rajesh, et al.
Publicado: (2015)

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease
por: Sharma, Vibhash D, et al.
Publicado: (2018)

Molecular docking investigation of the amantadine binding to the enzymes upregulated or downregulated in Parkinson’s disease
por: Ionescu, Mihaela Ileana
Publicado: (2020)

Progressive Supranuclear Palsy—Parkinsonism Predominant (PSP-P)—A Clinical Challenge at the Boundaries of PSP and Parkinson's Disease (PD)
por: Alster, Piotr, et al.
Publicado: (2020)

Serum amino acid profile in patients with Parkinson’s disease
por: Figura, Monika, et al.
Publicado: (2018)

Erratum to: Neuroprotective effect of Spirulina fusiform and amantadine in the 6-OHDA induced Parkinsonism in rats
por: Chattopadhyaya, I., et al.
Publicado: (2015)

Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial
por: Kim, Aryun, et al.
Publicado: (2018)

Amantadine in Treatment of Dysthymia—The Pilot Case Series Study
por: Krzystanek, Marek, et al.
Publicado: (2023)

Amantadine Effect on Perceptions of Irritability after Traumatic Brain Injury: Results of the Amantadine Irritability Multisite Study
por: Hammond, Flora M., et al.
Publicado: (2015)

Computer Aided Written Character Feature Extraction in Progressive Supranuclear Palsy and Parkinson’s Disease
por: Stępień, Paula, et al.
Publicado: (2022)

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102
por: Isaacson, Stuart H., et al.
Publicado: (2018)

Effect of Repeated Intravenous Amantadine Infusions in Patients with Parkinson's Disease: An Open‐Label Pilot Study
por: Khlebtovsky, Alexander, et al.
Publicado: (2019)

Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease
por: Hauser, Robert A., et al.
Publicado: (2022)

Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease
por: Fan, Qian-Ya, et al.
Publicado: (2022)

The Neuro-Ophthalmological Assessment in Parkinson’s Disease
por: Borm, Carlijn D.J.M., et al.
Publicado: (2019)

Amantadine Treatment for People with COVID-19
por: Araújo, Ramiro, et al.
Publicado: (2020)

Paraneoplastic Chorea Managed with Intravenous Amantadine
por: Doher, Nicholas, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ooajqjr2h0eg46ca901ubcss5s